Photo taken from Elisa Agostinetto/LinkedIn
May 20, 2024, 11:18
Elisa Agostinetto: Our review on emerging treatments for HER2+ breast cancer
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on LinkedIn:
“Now out in Cell Reports Medicine, our review on emerging treatments for HER2+ breast cancer.
We discuss how survival improvements in this disease set a high bar for new drug development and the need to explore new ways to overcome resistance mechanisms.”
Additional information.
Source: Elisa Agostinetto/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 19:25
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08